Cargando…

The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial

INTRODUCTION/OBJECTIVES: To evaluate changes in health-related quality of life (HRQoL) and productivity following treatment with intravenous (IV) golimumab in patients with psoriatic arthritis (PsA). METHODS: Patients were randomized to IV golimumab 2 mg/kg (n=241) at Weeks 0, 4, then every 8 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogdie, Alexis, Walsh, Jessica A., Chakravarty, Soumya D., Peterson, Steven, Lo, Kim Hung, Kim, Lilianne, Li, Nan, Hsia, Elizabeth C., Chan, Eric K. H., Kavanaugh, Arthur, Husni, M. Elaine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357705/ https://www.ncbi.nlm.nih.gov/pubmed/33655380 http://dx.doi.org/10.1007/s10067-021-05639-1

Ejemplares similares

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty‐Four of the GO‐VIBRANT Study
por: Kavanaugh, Arthur, et al.
Publicado: (2017)

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study
por: Mease, Philip, et al.
Publicado: (2020)

Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis
por: Husni, M. Elaine, et al.
Publicado: (2020)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Husni, M. Elaine, et al.
Publicado: (2022)

Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial
por: Mease, Philip, et al.
Publicado: (2020)

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2022)

Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2023)

Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen‐B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study
por: Deodhar, Atul A., et al.
Publicado: (2022)

Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials
por: Gensler, L. S., et al.
Publicado: (2020)

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab
por: Wagner, Carrie L, et al.
Publicado: (2013)

Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
por: Tesser, John, et al.
Publicado: (2022)

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Kay, Jonathan, et al.
Publicado: (2015)

Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
por: McInnes, Iain B, et al.
Publicado: (2019)

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
por: Michelon, Melissa A, et al.
Publicado: (2010)

Obesity and Psoriatic Arthritis: A Narrative Review
por: Kumthekar, Anand, et al.
Publicado: (2020)

Psoriatic arthritis: prospects for the future
por: Hackett, Simon, et al.
Publicado: (2022)

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany
por: Krüger, Klaus, et al.
Publicado: (2018)

Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations
por: McIntosh, Sydney Moore, et al.
Publicado: (2023)

Treatment guidelines in psoriatic arthritis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
por: Kavanaugh, Arthur, et al.
Publicado: (2013)

Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial
por: Weinblatt, Michael E, et al.
Publicado: (2014)

Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations
por: Leu, Jocelyn H., et al.
Publicado: (2022)

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
por: Kavanaugh, Arthur, et al.
Publicado: (2014)

Probiotic Use and Psoriatic Arthritis Disease Activity
por: Grinnell, Madison, et al.
Publicado: (2020)

Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis
por: Ogdie, Alexis, et al.
Publicado: (2021)

A Case of Nail Psoriasis Improved by Treatment with Golimumab in a Psoriatic Arthritis Patient
por: Jung, So Young
Publicado: (2017)

Psoriatic arthritis and the association with cardiometabolic disease: a narrative review
por: Karmacharya, Paras, et al.
Publicado: (2021)

Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

First Reported Mycobacterium Marinum Infection Case in a Patient With Psoriatic Arthritis Maintained on Golimumab
por: RIDA, Mohamad Ali, et al.
Publicado: (2020)

Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement
por: Chimenti, Maria Sole, et al.
Publicado: (2021)

Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study
por: Kavanaugh, Arthur, et al.
Publicado: (2016)

Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany
por: Krüger, Klaus, et al.
Publicado: (2018)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
por: Coates, Laura C., et al.
Publicado: (2022)

The impact of identifying carotid plaque on addressing cardiovascular risk in psoriatic arthritis
por: Lucke, Michael, et al.
Publicado: (2016)

Psoriatic arthritis: Pathogenesis and novel immunomodulatory approaches to treatment
por: Cassell, Sarah, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_m61hdt917ldim9ukqdg1698o4n